Cite

HARVARD Citation

    Matos Garcia, I. et al. (n.d.). 1841PRefining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability. Annals of oncology. p. . [Online]. 
  
Back to record